dalteparin has been researched along with Hepatic Failure in 7 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seijo, S | 1 |
| Garcia-Pagan, JC | 1 |
| Giannini, EG | 1 |
| Stravitz, RT | 1 |
| Caldwell, SH | 1 |
| Tronina, O | 1 |
| Mikołajczyk, N | 1 |
| Pietrzak, B | 1 |
| Pacholczyk, M | 1 |
| Durlik, M | 1 |
| Villa, E | 2 |
| Cammà, C | 2 |
| Marietta, M | 1 |
| Luongo, M | 1 |
| Critelli, R | 1 |
| Colopi, S | 1 |
| Tata, C | 1 |
| Zecchini, R | 1 |
| Gitto, S | 1 |
| Petta, S | 1 |
| Lei, B | 1 |
| Bernabucci, V | 1 |
| Vukotic, R | 1 |
| De Maria, N | 1 |
| Schepis, F | 1 |
| Karampatou, A | 1 |
| Caporali, C | 1 |
| Simoni, L | 1 |
| Del Buono, M | 1 |
| Zambotto, B | 1 |
| Turola, E | 1 |
| Fornaciari, G | 1 |
| Schianchi, S | 1 |
| Ferrari, A | 1 |
| Valla, D | 2 |
| Fontana, RJ | 1 |
| Senzolo, M | 1 |
| Caldwell, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis[NCT04874428] | Phase 1 | 24 participants (Anticipated) | Interventional | 2021-05-19 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dalteparin and Hepatic Failure
| Article | Year |
|---|---|
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.
Topics: Anticoagulants; Bacterial Infections; Bacterial Translocation; Biomarkers; DNA, Bacterial; Enoxapari | 2012 |
6 other studies available for dalteparin and Hepatic Failure
| Article | Year |
|---|---|
Anticoagulation in cirrhosis: ready … set … wait!
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2013 |
Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis.
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2014 |
Pregnancy in a patient with hepatic artery thrombosis after liver transplantation: a case report.
Topics: Activated Protein C Resistance; Adult; Anticoagulants; Collateral Circulation; Enoxaparin; Female; H | 2014 |
Prophylactic anticoagulation in cirrhotics: a paradox for prime time?
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2012 |
Portal vein thrombosis in cirrhosis: ignore, prevent, or treat?
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2013 |
Reply: To PMID 22819864.
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2013 |